UNSPSC 51263307: Ecastolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C26H33N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEB95DS30P, chemically known as (- )-4-(3-((3,4-dimethoxy-phenethyl)amino)-2-hydroxypropoxy)-3-(5-isoxazolyl)butyranilide. but generally known as ecastolol, which bears US NIH Compound Identifier 208905. European Medicines Agency schedules Ecastolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06444MIG.

UNSPSC 51263307 Ecastolol is a Commodity code, but the recent state and local opportunities tagged under it reflect procurement of naloxone and drug deactivation systems rather than ecastolol specifically, indicating a significant mismatch between the code's nominal scope and the work actually being solicited. The opportunities show state and local health and human services agencies buying naloxone supply, safe drug deactivation equipment, and exploring direct-to-manufacturer pharmacy benefit models to support opioid response and prescription management initiatives.

Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting between state pharmacy benefit programs and manufacturers to improve prescription fulfillment efficiency. The issuing bodies span county health departments and state HHS commissions. Geographically, recent activity appears in Florida and Texas. The code shows little relevant recent activity under its stated nomenclature, suggesting that vendors pursuing opportunities in pharmaceutical supply and health services procurement should verify actual commodity classifications in individual solicitations rather than relying on the code's abstract designation.